Thursday, October 27, 2016

Biotech Stocks Facing FDA Decision In November

It looks like 2016 is going to be a relatively lackluster year in terms of new drug approvals. Only 18 new molecular entity drugs have been approved year-to-date compared to 32 approved during the same time frame last year.

from RTT - Biotech http://ift.tt/2eVXFC3
via IFTTT

No comments:

Post a Comment